A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Scott Saxman, Beth Mann, Vikki Canfield, Patrick Loehrer, Everett Vokes

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Forty patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated weekly with vinorelbine 30 mg/m2. Thirty-five patients received prior surgery, 20 prior chemotherapy, and 38 prior radiation therapy. Five patients were not evaluable for response and were assumed to be nonresponders. There were three confirmed responders (one complete response, two partial responses) for a response rate of 7.5% (95% confidence interval, 1.6%-20.4%). The median survival time for all patients was 5 months (range, 0.5-50 months), the median progression-free survival time was 2 months (range, 1-49 months). The most common toxicity was myelosuppression, with 60% of patients experiencing grade 3 or higher leukopenia. There was one treatment-related death resulting from sepsis. Vinorelbine has minimal activity in patients with SCCHN that does not exceed that of other currently used agents.

Original languageEnglish
Pages (from-to)398-400
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume21
Issue number4
DOIs
StatePublished - Aug 1998

Fingerprint

Leukopenia
Disease-Free Survival
vinorelbine
Carcinoma, squamous cell of head and neck
Sepsis
Radiotherapy
Confidence Intervals
Drug Therapy
Survival
Therapeutics

Keywords

  • Head and neck cancer
  • Navelbine
  • Phase II trial
  • Squamous cell carcinoma
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. / Saxman, Scott; Mann, Beth; Canfield, Vikki; Loehrer, Patrick; Vokes, Everett.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 21, No. 4, 08.1998, p. 398-400.

Research output: Contribution to journalArticle

@article{07daad5be0f6459f909684cd09fa4163,
title = "A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck",
abstract = "Forty patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated weekly with vinorelbine 30 mg/m2. Thirty-five patients received prior surgery, 20 prior chemotherapy, and 38 prior radiation therapy. Five patients were not evaluable for response and were assumed to be nonresponders. There were three confirmed responders (one complete response, two partial responses) for a response rate of 7.5{\%} (95{\%} confidence interval, 1.6{\%}-20.4{\%}). The median survival time for all patients was 5 months (range, 0.5-50 months), the median progression-free survival time was 2 months (range, 1-49 months). The most common toxicity was myelosuppression, with 60{\%} of patients experiencing grade 3 or higher leukopenia. There was one treatment-related death resulting from sepsis. Vinorelbine has minimal activity in patients with SCCHN that does not exceed that of other currently used agents.",
keywords = "Head and neck cancer, Navelbine, Phase II trial, Squamous cell carcinoma, Vinorelbine",
author = "Scott Saxman and Beth Mann and Vikki Canfield and Patrick Loehrer and Everett Vokes",
year = "1998",
month = "8",
doi = "10.1097/00000421-199808000-00016",
language = "English",
volume = "21",
pages = "398--400",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

AU - Saxman, Scott

AU - Mann, Beth

AU - Canfield, Vikki

AU - Loehrer, Patrick

AU - Vokes, Everett

PY - 1998/8

Y1 - 1998/8

N2 - Forty patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated weekly with vinorelbine 30 mg/m2. Thirty-five patients received prior surgery, 20 prior chemotherapy, and 38 prior radiation therapy. Five patients were not evaluable for response and were assumed to be nonresponders. There were three confirmed responders (one complete response, two partial responses) for a response rate of 7.5% (95% confidence interval, 1.6%-20.4%). The median survival time for all patients was 5 months (range, 0.5-50 months), the median progression-free survival time was 2 months (range, 1-49 months). The most common toxicity was myelosuppression, with 60% of patients experiencing grade 3 or higher leukopenia. There was one treatment-related death resulting from sepsis. Vinorelbine has minimal activity in patients with SCCHN that does not exceed that of other currently used agents.

AB - Forty patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated weekly with vinorelbine 30 mg/m2. Thirty-five patients received prior surgery, 20 prior chemotherapy, and 38 prior radiation therapy. Five patients were not evaluable for response and were assumed to be nonresponders. There were three confirmed responders (one complete response, two partial responses) for a response rate of 7.5% (95% confidence interval, 1.6%-20.4%). The median survival time for all patients was 5 months (range, 0.5-50 months), the median progression-free survival time was 2 months (range, 1-49 months). The most common toxicity was myelosuppression, with 60% of patients experiencing grade 3 or higher leukopenia. There was one treatment-related death resulting from sepsis. Vinorelbine has minimal activity in patients with SCCHN that does not exceed that of other currently used agents.

KW - Head and neck cancer

KW - Navelbine

KW - Phase II trial

KW - Squamous cell carcinoma

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0031819276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031819276&partnerID=8YFLogxK

U2 - 10.1097/00000421-199808000-00016

DO - 10.1097/00000421-199808000-00016

M3 - Article

VL - 21

SP - 398

EP - 400

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -